Biosdue secures over 50% of Snia:
This article was originally published in Clinica
Italian financial company Biosdue, a wholly-owned subsidiary of holding company Bios, has announced that it holds 50.1% of biomedical and chemical group Snia, after launching a bid for full control in February (see Clinica No 984, p 15). Bios already owned a 28.3% majority stake in Snia. The group is expected to focus on its biomedical activities, according to comments made by Emilio Gnutti, head of Bios, in an interview with Italian daily Il Sole 24 Ore. Approximately half of Snia's revenues are generated through its medical technology division.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.